Screener
Globus Medical GMED Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Globus Medical in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Globus Medical’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054450
| (In thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Depreciation and amortization | 139,355 | 136,284 |
| Provision for excess and obsolete inventory | 9,795 | 10,933 |
| Amortization of acquisition accounting fair value step up | — | 12,673 |
| Stock-based compensation expense | 26,000 | 26,823 |
| Allowance for expected credit losses | 10,398 | 4,554 |
| Change in fair value of business acquisition liabilities | 16,059 | 5,389 |
| Change in deferred income taxes | 15,748 | (41,236) |
| (Gain)/loss on disposal of assets, net | 5,558 | 6,131 |
Item 1. Financial Statements
FAQ
- What is Globus Medical's stock-based comp?
- Globus Medical (GMED) reported stock-based comp of $13.38M in Q2 2026.
- How has Globus Medical's stock-based comp changed year-over-year?
- Globus Medical's stock-based comp decreased by 1.7% year-over-year, from $13.62M to $13.38M.
- What is the long-term trend for Globus Medical's stock-based comp?
- Over 4 years (2021 to 2025), Globus Medical's stock-based comp has grown at a 12.9% compound annual growth rate (CAGR), from $30.59M to $49.78M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Globus Medical's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude